When used to treat colonic inflammation induced by TNBS administration to Balb/c mice, ciprofloxacin effectively protected against development of local signs of colitis and markedly reduced local generation of inflammatory mediators including IL-1β, IL-6, IFNγ and TNFα. The gene discussed is IL1B; the disease is colitis.